Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.56 |
| ▸ | PI4KA | P42356 | 10/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9120 | 0.86 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22399264 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24239210 | 0.78 | CDK1 (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28004601 | 0.78 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28004916 | 0.78 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22326711 | 0.77 | CYP1A2 (0.49) | ADORA2AADORA1 | |
| SCHEMBL22402773 | 0.77 | FLT4 (0.42) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28210687 | 0.76 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL48453 | 0.75 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29138713 | 0.74 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071747-B2 | Use of NAD precursors for breast enhancement | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210106606-A1 | USE OF NAD PRECURSORS FOR IMPROVING MATERNAL HEALTH AND/OR OFFSPRING HEALTH | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-04-15 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190322696-A1 | 3'3'-CYCLIC DINUCLEOTIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2019-10-24 | — | — | US | disclosed |
| US-20180147225-A1 | USE OF NAD PRECURSORS FOR BREAST ENHANCEMENT | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071747-B2 | Use of NAD precursors for breast enhancement | NQO1, NNT, NAMPT | ADORA2A 102/4885ADORA1 161/4885PI4KA 3736/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 228/4885ADORA1 314/4885PI4KA 770/4885 |
| US-20190322696-A1 | 3'3'-CYCLIC DINUCLEOTIDES | STING1, CGAS, MAVS | ADORA2A 2610/4885ADORA1 3479/4885PI4KA 574/4885 |
| US-20180147225-A1 | USE OF NAD PRECURSORS FOR BREAST ENHANCEMENT | NQO1, NNT, NAMPT | ADORA2A 102/4885ADORA1 161/4885PI4KA 3736/4885 |
| US-20210106606-A1 | USE OF NAD PRECURSORS FOR IMPROVING MATERNAL HEALTH AND/OR OFFSPRING HEALTH | NQO1, NNT, SIRT3 | ADORA2A 473/4885ADORA1 607/4885PI4KA 4365/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | ADORA2A 900/4885ADORA1 1640/4885PI4KA 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.